Overview

Belimumab Impacting Transplant Eligibility

Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, open label, phase I/II pilot study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
E. Steve Woodle
Collaborator:
GlaxoSmithKline
Treatments:
Belimumab
Bortezomib
Rituximab